For the first time in Moldova the German Maintrac test for onko patients!

Now and in our country there is a modern way of determination of sensitivity of living tumor cells on anti-cancer therapy. This way is the German Maintrac test. This test is successfully used in more, than 60 countries in routine practice of oncologists more than 15 years. And in our country the official representative of the Maintrac test is the MilrayMC firm. The Maintrac test defines what of the tested preparations for the patient will be the most effective in his case, using for the analysis only 15 ml of a blue blood.

And if the patient already passes химиотерапию/гормонотерапию/радиотерапию/природную therapy or even any other alternative therapies, then control of success of this treatment is all the same possible. The Maintrac test podschityvayetzhivy cancer cells in blood of the patient for whom diagnosed and operated cancer.

These cages inevitably remain in the patient's body even after operation because they constantly extend a blood stream from primary tumor even before its removal and they are the reason of a metastazirovaniye or recurrence.

Thus periodic calculation of cages:
- after operation,
- after each two courses of chemotherapy,
- during the supporting chemotherapy, does possible control of therapy in real time, comparing every time their quantity to previous and gives the answer to a question: Whether "This therapy helps me or I in vain transfer all these intolerable side effects?". If the number of cages constantly increases it means that therapy is not effective and if their quantity decreases – treatment works.

When remission of Maintrac comes again comes to the rescue for control of a situation. Periodic calculation of quantity of the circulating cancer cells when cancer receded, can predict about possible recurrence. As soon as the quantity of cages sharply increases, it means development of new oncological process which is not swept up yet by technicians of visual diagnostics (ultrasonography, KT, MPT). In a consequence of it measures for the prevention of developing of a new tumor can be taken.

More than 20 Maintrac tests were already successfully sent for the analysis to Germany which results come to e-mail within at most 7 days, thus it gives the chance to our patients to be objectively informed on efficiency of the current treatment, on adequacy to the picked-up therapy, thereby having improved their quality of life and their psychological state.